[{"id":"dc0579d6-d285-4c4f-a4da-1f44bfe4d346","acronym":"","url":"https://clinicaltrials.gov/study/NCT06069024","created_at":"2023-10-05T16:11:22.043Z","updated_at":"2024-07-02T16:35:10.669Z","phase":"","brief_title":"Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide","source_id_and_acronym":"NCT06069024","lead_sponsor":"Qianfoshan Hospital","biomarkers":" ABCB1","pipe":"","alterations":" ","tags":["ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2024-04-09"},{"id":"68ee6666-a2a3-4022-9809-88a75276636f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04608409","created_at":"2024-03-01T20:31:47.689Z","updated_at":"2024-07-02T16:35:16.832Z","phase":"Phase 1","brief_title":"Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer","source_id_and_acronym":"NCT04608409","lead_sponsor":"Frederick R. Ueland, M.D.","biomarkers":" ABCB1","pipe":" | ","alterations":" ABCB1 expression","tags":["ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABCB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-01"},{"id":"bf025afb-cb7b-4218-a07e-2e1a6a998168","acronym":"VICTORIA","url":"https://clinicaltrials.gov/study/NCT02730923","created_at":"2021-01-18T13:22:14.129Z","updated_at":"2024-07-02T16:35:19.665Z","phase":"Phase 1/2","brief_title":"Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)","source_id_and_acronym":"NCT02730923 - VICTORIA","lead_sponsor":"Centre Leon Berard","biomarkers":" ER • PGR • ABCB1","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR • ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-13"},{"id":"b00fc8ee-1191-428e-8093-c4351326248c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00898456","created_at":"2021-01-18T03:27:05.038Z","updated_at":"2024-07-02T16:35:39.792Z","phase":"","brief_title":"Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT00898456","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ABCB1 • ABCG2 • ABCC1","pipe":"","alterations":" ","tags":["ABCB1 • ABCG2 • ABCC1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 10/01/2006","start_date":" 10/01/2006","primary_txt":" Primary completion: 01/01/2100","primary_completion_date":" 01/01/2100","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-17"},{"id":"03cc6bc8-5618-4603-9100-4c0895d92154","acronym":"","url":"https://clinicaltrials.gov/study/NCT00295919","created_at":"2021-01-18T01:00:35.845Z","updated_at":"2024-07-02T16:35:51.193Z","phase":"Phase 1","brief_title":"N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma","source_id_and_acronym":"NCT00295919","lead_sponsor":"Children's Hospital Los Angeles","biomarkers":" ABCB1","pipe":"","alterations":" ","tags":["ABCB1"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 12/01/2005","start_date":" 12/01/2005","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 05/01/2015","study_completion_date":" 05/01/2015","last_update_posted":"2023-04-07"},{"id":"12924476-298c-4897-ac2b-80b4055a3dad","acronym":"IV Fenretinide","url":"https://clinicaltrials.gov/study/NCT00646230","created_at":"2021-01-18T02:24:16.941Z","updated_at":"2024-07-02T16:35:51.086Z","phase":"Phase 1","brief_title":"N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma","source_id_and_acronym":"NCT00646230 - IV Fenretinide","lead_sponsor":"Nant Operations Center","biomarkers":" ABCB1","pipe":"","alterations":" ","tags":["ABCB1"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 12/01/2006","start_date":" 12/01/2006","primary_txt":" Primary completion: 03/01/2012","primary_completion_date":" 03/01/2012","study_txt":" Completion: 03/01/2012","study_completion_date":" 03/01/2012","last_update_posted":"2023-04-07"},{"id":"2ceeeb8d-e04f-450c-96bb-1835a4138640","acronym":"","url":"https://clinicaltrials.gov/study/NCT05326984","created_at":"2022-04-14T12:53:51.933Z","updated_at":"2024-07-02T16:36:12.452Z","phase":"","brief_title":"Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05326984","lead_sponsor":"Hospital General de Mexico","biomarkers":" ABCB1 • AMPK","pipe":" | ","alterations":" ABCB1 expression • AMPK expression","tags":["ABCB1 • AMPK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABCB1 expression • AMPK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/09/2021","start_date":" 02/09/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-14"},{"id":"35b097a8-236d-4100-8ac8-8041f2ce0d05","acronym":"CORIST","url":"https://clinicaltrials.gov/study/NCT04247256","created_at":"2021-01-18T20:38:38.588Z","updated_at":"2024-07-02T16:36:16.327Z","phase":"Phase 2","brief_title":"A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI","source_id_and_acronym":"NCT04247256 - CORIST","lead_sponsor":"Scandion Oncology A/S","biomarkers":" KRAS • BRAF • ABCB1 • ABCG2 • UGT1A1 • SRPK1","pipe":" | ","alterations":" BRAF mutation • UGT1A1*1*1","tags":["KRAS • BRAF • ABCB1 • ABCG2 • UGT1A1 • SRPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • endovion (SCO-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/14/2020","start_date":" 05/14/2020","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2022-03-01"},{"id":"296c96e7-b22e-4040-a519-2e7ecf12e1f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03147378","created_at":"2021-10-19T13:55:36.804Z","updated_at":"2024-07-02T16:36:22.779Z","phase":"Phase 1","brief_title":"Food Effect Study of ModraDoc006 in Combination With Ritonavir","source_id_and_acronym":"NCT03147378","lead_sponsor":"Modra Pharmaceuticals","biomarkers":" ABCB1 • ABCC2","pipe":"","alterations":" ","tags":["ABCB1 • ABCC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel oral/ritonavir (ModraDoc006/r)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/10/2017","start_date":" 05/10/2017","primary_txt":" Primary completion: 04/04/2018","primary_completion_date":" 04/04/2018","study_txt":" Completion: 04/04/2018","study_completion_date":" 04/04/2018","last_update_posted":"2021-10-19"},{"id":"24564cf4-dd6c-4128-b446-ac0dcc6000d1","acronym":"PRECISE","url":"https://clinicaltrials.gov/study/NCT03933761","created_at":"2021-01-18T19:22:29.887Z","updated_at":"2024-07-02T16:36:26.727Z","phase":"Phase 2","brief_title":"Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy","source_id_and_acronym":"NCT03933761 - PRECISE","lead_sponsor":"Australia New Zealand Gynaecological Oncology Group","biomarkers":" BRCA1 • BRCA2 • ABCB1 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • ABCB1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Partruvix (pamiparib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/29/2019","start_date":" 07/29/2019","primary_txt":" Primary completion: 08/02/2021","primary_completion_date":" 08/02/2021","study_txt":" Completion: 08/02/2021","study_completion_date":" 08/02/2021","last_update_posted":"2021-08-10"},{"id":"f7d3af2d-893c-4bf6-9abf-f191804b1e33","acronym":"","url":"https://clinicaltrials.gov/study/NCT04654195","created_at":"2021-01-19T20:41:14.703Z","updated_at":"2024-07-02T16:36:37.836Z","phase":"","brief_title":"Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient","source_id_and_acronym":"NCT04654195","lead_sponsor":"Damanhour University","biomarkers":" ABCB1","pipe":"","alterations":" ","tags":["ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2020-12-04"},{"id":"aa064749-2966-4885-b3cb-bf7feeac3424","acronym":"OVIMA-1210","url":"https://clinicaltrials.gov/study/NCT02197637","created_at":"2021-01-18T10:16:35.601Z","updated_at":"2024-07-02T16:36:38.543Z","phase":"Phase 2","brief_title":"Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma","source_id_and_acronym":"NCT02197637 - OVIMA-1210","lead_sponsor":"Centre Oscar Lambret","biomarkers":" ABCB1 • CYP3A5","pipe":"","alterations":" ","tags":["ABCB1 • CYP3A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 08/01/2019","primary_completion_date":" 08/01/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2020-11-18"},{"id":"83628572-2bd7-4286-9103-ae047ded58c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00880503","created_at":"2021-01-18T03:22:07.754Z","updated_at":"2024-07-02T16:36:52.477Z","phase":"","brief_title":"Collection of Tissue Samples for Study of Multidrug Resistance","source_id_and_acronym":"NCT00880503","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABCB1","pipe":"","alterations":" ","tags":["ABCB1"],"overall_status":"Completed","enrollment":" Enrollment 325","initiation":"Initiation: 12/19/2003","start_date":" 12/19/2003","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 02/08/2018","study_completion_date":" 02/08/2018","last_update_posted":"2019-12-16"},{"id":"b3262a6b-d00b-4895-ac67-d29d40fc7de5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923884","created_at":"2021-01-18T03:34:38.850Z","updated_at":"2024-07-02T16:36:54.725Z","phase":"","brief_title":"Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer","source_id_and_acronym":"NCT00923884","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABCB1 • CYP1B1","pipe":"","alterations":" ","tags":["ABCB1 • CYP1B1"],"overall_status":"Completed","enrollment":" Enrollment 546","initiation":"Initiation: 03/18/2009","start_date":" 03/18/2009","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 04/20/2018","study_completion_date":" 04/20/2018","last_update_posted":"2019-10-09"},{"id":"488ef063-a283-4c77-b64f-3176825e4e9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03659162","created_at":"2022-06-12T20:55:12.676Z","updated_at":"2024-07-02T16:37:07.175Z","phase":"","brief_title":"Efflux Pump Mediated Azole Resistance in Candida Albicans","source_id_and_acronym":"NCT03659162","lead_sponsor":"Assiut University","biomarkers":" ABCB1 • CDR2","pipe":"","alterations":" ","tags":["ABCB1 • CDR2"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 02/17/2019","start_date":" 02/17/2019","primary_txt":" Primary completion: 04/10/2019","primary_completion_date":" 04/10/2019","study_txt":" Completion: 07/24/2019","study_completion_date":" 07/24/2019","last_update_posted":"2018-09-06"},{"id":"0fed4813-2327-42f4-8f7e-67b0a8ca6e06","acronym":"","url":"https://clinicaltrials.gov/study/NCT00679354","created_at":"2021-01-18T02:32:24.165Z","updated_at":"2024-07-02T16:37:08.366Z","phase":"Phase 2","brief_title":"Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy","source_id_and_acronym":"NCT00679354","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABCB1 • ABCG2","pipe":"","alterations":" ","tags":["ABCB1 • ABCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cilcane (cilengitide)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 07/01/2011","study_completion_date":" 07/01/2011","last_update_posted":"2018-08-01"},{"id":"6542aa09-5976-44cf-8c7d-20752d3890cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00389818","created_at":"2021-01-18T01:21:26.962Z","updated_at":"2024-07-02T16:37:10.318Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00389818","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" BCL2 • CD20 • ABCB1 • CD4","pipe":" | ","alterations":" CD20 positive • BCL2 expression","tags":["BCL2 • CD20 • ABCB1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • Neulasta (pegfilgrastim) • Leukine (sargramostim) • Neupogen (filgrastim) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 01/01/2007","start_date":" 01/01/2007","primary_txt":" Primary completion: 09/01/2011","primary_completion_date":" 09/01/2011","study_txt":" Completion: 09/01/2011","study_completion_date":" 09/01/2011","last_update_posted":"2018-06-06"},{"id":"802e795f-56e0-488a-b4d6-7a57a6c0ed3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03118128","created_at":"2021-01-18T15:21:45.733Z","updated_at":"2024-07-02T16:37:20.163Z","phase":"","brief_title":"Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03118128","lead_sponsor":"Hospital General de Mexico","biomarkers":" ABCB1","pipe":"","alterations":" ","tags":["ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 04/30/2017","study_completion_date":" 04/30/2017","last_update_posted":"2017-07-06"}]